Citigroup Inc. Purchases 101,166 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Citigroup Inc. grew its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 55.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 282,862 shares of the company’s stock after buying an additional 101,166 shares during the period. Citigroup Inc. owned approximately 0.09% of Amneal Pharmaceuticals worth $2,831,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in AMRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Amneal Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock worth $793,000 after purchasing an additional 4,178 shares during the last quarter. Millennium Management LLC boosted its position in shares of Amneal Pharmaceuticals by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock valued at $17,492,000 after buying an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Amneal Pharmaceuticals in the 1st quarter worth about $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Amneal Pharmaceuticals by 5.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock worth $2,807,000 after buying an additional 16,536 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its position in Amneal Pharmaceuticals by 12.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 42,124 shares of the company’s stock worth $341,000 after buying an additional 4,596 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on AMRX shares. Barclays started coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target for the company. Truist Financial lifted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $14.20.

Amneal Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ AMRX opened at $13.24 on Friday. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $15.42. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 57.57 and a beta of 1.35. The firm has a 50 day moving average of $13.79 and a 200 day moving average of $11.87.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.